Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide, quantity: 100 microgram/ml - injection, solution - excipient ingredients: water for injections; mannitol; sodium bicarbonate; lactic acid - for symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy or dopamine agonist treatment. sandostatin treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: carcinoid tumours with features of the carcinoid syndrome; vasoactive intestinal peptide secreting tumours (vipomas). sandostatin is not curative in these patients. for reduction of the incidence of complications following pancreatic surgery.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - octreotide, quantity: 50 microgram/ml - injection, solution - excipient ingredients: water for injections; mannitol; lactic acid; sodium bicarbonate - for symptomatic control and reduction of growth hormone and igf-1 plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy or dopamine agonist treatment. sandostatin treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective. for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: carcinoid tumours with features of the carcinoid syndrome; vasoactive intestinal peptide secreting tumours (vipomas). sandostatin is not curative in these patients. for reduction of the incidence of complications following pancreatic surgery.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - octreotide, quantity: 50 microgram - injection, solution - excipient ingredients: water for injections; sodium chloride; glacial acetic acid; sodium acetate trihydrate - for symptomatic control and reduction of growth hormone and igf-l plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment. octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - carcinoid tumours with features of the carcinoid syndrome - vasoactive intestinal peptide secreting tumours [vipomas] octreotide is not curative in these patients.,for reduction of the incidence of complications following pancreatic surgery.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - octreotide, quantity: 100 microgram - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium acetate trihydrate; glacial acetic acid - for symptomatic control and reduction of growth hormone and igf-l plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment. octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - carcinoid tumours with features of the carcinoid syndrome - vasoactive intestinal peptide secreting tumours [vipomas] octreotide is not curative in these patients.,for reduction of the incidence of complications following pancreatic surgery.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - octreotide, quantity: 500 microgram - injection, solution - excipient ingredients: water for injections; sodium acetate trihydrate; glacial acetic acid; sodium chloride - for symptomatic control and reduction of growth hormone and igf-l plasma levels in patients with acromegaly, including those who are inadequately controlled by surgery, radiotherapy, or dopamine agonist treatment. octreotide treatment is also indicated in acromegalic patients unfit or unwilling to undergo surgery, or in the interim period until radiotherapy becomes fully effective.,for the relief of symptoms associated with the following functional tumours of the gastro-entero-pancreatic endocrine system: - carcinoid tumours with features of the carcinoid syndrome - vasoactive intestinal peptide secreting tumours [vipomas] octreotide is not curative in these patients.,for reduction of the incidence of complications following pancreatic surgery.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydromorphone hydrochloride, quantity: 50 mg - injection, concentrated - excipient ingredients: sodium chloride; citric acid monohydrate; sodium citrate; water for injections - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydromorphone hydrochloride, quantity: 2 mg - injection, solution - excipient ingredients: water for injections; sodium citrate; citric acid monohydrate; sodium chloride - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydromorphone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: sodium citrate; water for injections; sodium chloride; citric acid monohydrate - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

orthomolecular medisearch laboratories pty ltd trading as biological therapies - cyanocobalamin, quantity: 1 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid; sodium chloride - 1. pernicious anaemia as a result of in situ b12 deficiency.

Avstralija - angleščina - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - ephedrine sulfate, quantity: 30 mg/ml - injection, solution - excipient ingredients: sodium chloride; water for injections - ephedrine is indicated in the treatment of shock unresponsive to fluid replacement. it is also indicated in the treatment of hypotension secondary to spinal anaesthesia. ephedrine sulfate injection has also been used in the treatment of bronchial asthma and reversible bronchospasm although more selective agents (beta adrenergic agonists) are now available.